akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Company profile
Ticker
AKBA
Exchange
Website
CEO
John Butler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Akebia Therapeutics Securities Corporation • Akebia Europe Limited • Keryx Biopharmaceuticals, Inc. • ACCESS Oncology, Inc. • AOI Pharma, Inc. • AOI Pharmaceuticals, Inc. • Online Collaborative Oncology Group, Inc. • Accumin Diagnostics, Inc. • Neryx Biopharmaceuticals, Inc. • Keryx Biopharma UK Ltd. ...
AKBA stock data
Latest filings (excl ownership)
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
23 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Apr 24
8-K
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
27 Mar 24
8-K
Departure of Directors or Certain Officers
15 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K
Departure of Directors or Certain Officers
13 Feb 24
S-8
Registration of securities for employees
30 Jan 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
8-K
Departure of Directors or Certain Officers
8 Jan 24
Transcripts
AKBA
Earnings call transcript
2023 Q3
8 Nov 23
AKBA
Earnings call transcript
2023 Q2
25 Aug 23
AKBA
Earnings call transcript
2023 Q1
8 May 23
AKBA
Earnings call transcript
2022 Q4
9 Mar 23
AKBA
Earnings call transcript
2022 Q3
3 Nov 22
AKBA
Earnings call transcript
2022 Q2
6 Aug 22
AKBA
Earnings call transcript
2022 Q1
10 May 22
AKBA
Earnings call transcript
2021 Q3
9 Nov 21
AKBA
Earnings call transcript
2021 Q2
5 Aug 21
AKBA
Earnings call transcript
2021 Q1
10 May 21
Latest ownership filings
4
Michel Dahan
1 Mar 24
4
Nicole R. Hadas
1 Mar 24
4
John P. Butler
1 Mar 24
4
Steven Keith Burke
1 Mar 24
4
Nicole R. Hadas
29 Feb 24
4
Michel Dahan
29 Feb 24
4
Steven Keith Burke
29 Feb 24
4
John P. Butler
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 48.18 mm | 48.18 mm | 48.18 mm | 48.18 mm | 48.18 mm | 48.18 mm |
Cash burn (monthly) | 2.37 mm | 8.31 mm | 4.35 mm | 4.38 mm | 2.39 mm | 6.31 mm |
Cash used (since last report) | 16.28 mm | 57.00 mm | 29.82 mm | 30.02 mm | 16.39 mm | 43.32 mm |
Cash remaining | 31.90 mm | -8.82 mm | 18.36 mm | 18.15 mm | 31.78 mm | 4.85 mm |
Runway (months of cash) | 13.4 | -1.1 | 4.2 | 4.1 | 13.3 | 0.8 |
Institutional ownership, Q3 2023
23.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 77 |
Opened positions | 7 |
Closed positions | 8 |
Increased positions | 18 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 47.75 bn |
Total shares | 49.13 mm |
Total puts | 188.80 k |
Total calls | 402.90 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Satter Management | 16.21 mm | $18.47 bn |
Vanguard | 7.52 mm | $8.57 bn |
Acadian Asset Management | 7.22 mm | $8.23 mm |
Renaissance Technologies | 3.16 mm | $3.59 bn |
Millennium Management | 3.05 mm | $3.48 bn |
BLK Blackrock | 2.45 mm | $2.80 bn |
Geode Capital Management | 1.72 mm | $1.97 bn |
FHI Federated Hermes Inc - Ordinary Shares | 965.19 k | $1.10 bn |
Victory Capital Management | 755.49 k | $861.26 mm |
Susquehanna International | 750.44 k | $855.50 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Steven Keith Burke | Common Stock | Sell | Dispose S | No | No | 1.58 | 7,169 | 11.33 k | 695,840 |
29 Feb 24 | Michel Dahan | Common Stock | Sell | Dispose S | No | No | 1.58 | 8,661 | 13.68 k | 706,932 |
29 Feb 24 | Nicole R. Hadas | Common Stock | Sell | Dispose S | No | No | 1.58 | 5,974 | 9.44 k | 663,259 |
29 Feb 24 | John P. Butler | Common Stock | Sell | Dispose S | No | No | 1.58 | 46,570 | 73.58 k | 2,044,580 |
27 Feb 24 | Nicole R. Hadas | Common Stock | Sell | Dispose S | No | No | 1.52 | 7,411 | 11.26 k | 669,233 |
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
10 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
29 Mar 24
10 Health Care Stocks With Whale Alerts In Today's Session
28 Mar 24
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6
28 Mar 24
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
28 Mar 24
Press releases
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24
Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?
1 Apr 24
Thinking about buying stock in Ocugen, Akebia Therapeutics, Mind Medicine, SoundHound AI, or Canopy Growth?
28 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
27 Mar 24
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
26 Mar 24